Merck, Pfizer execs explain how they tap sites for cancer trials

Good data are essential for staying competitive in the world of cancer drug development.

Pfizer and Merck & Co. know the requirement well, as they operate in the increasingly crowded immuno-oncology field. Just among themselves, the companies face off in three different cancer markets with their respective drugs Bavencio and Keytruda.